Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.51 |
| ▸ | MTOR | P42345 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 10/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24766568 | 0.74 | ATR (0.57) | — | |
| SCHEMBL17204101 | 0.74 | MAPT (0.61) | MEN1POLBKMT2ACYP1A2CYP2D6 | |
| SCHEMBL24766591 | 0.74 | CNR2 (0.46) | PIK3CAMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL29434142 | 0.73 | CDK1 (0.52) | PIK3CAMTORCYP1A2CYP2D6MAPT | |
| SCHEMBL24766835 | 0.73 | CDK1 (0.52) | PIK3CAMTORCYP1A2CYP2D6MAPT | |
| SCHEMBL245771 | 0.73 | MAPT (0.61) | PIK3CAMTORMEN1POLBKMT2A | |
| SCHEMBL29762483 | 0.73 | MAPT (0.61) | PIK3CAMTORMEN1POLBKMT2A | |
| SCHEMBL24766035 | 0.73 | MAPT (0.43) | PIK3CAMEN1POLBKMT2ACYP1A2 | |
| SCHEMBL24766067 | 0.72 | LRRK2 (0.48) | PIK3CAMTORKMT2ACYP1A2CYP2D6 | |
| SCHEMBL24766004 | 0.71 | MTOR (0.43) | PIK3CAMTORMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022060996-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | PIK3CA 61/4885MTOR 509/4885MEN1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.